The rules of the health insurance balance have been issued, and the transformation of pharmaceutical companies is imminent.

"
Pharmaceutical Network Industry Dynamic" Recently, the State Health Insurance Administration, the Ministry of Finance jointly issued on the national organization of drug centralized procurement work in the health insurance fund balance retention guidance in the industry spreadSome people in the industry believe that this policy will be the third batch of the country to collect the volume, quotations, the actual procurement volume will have a huge impact, and even change the future market competition patternWhat exactly is the balance of the collection of health insurance funds retained? According to the documents, in fact, the fixed-point hospital uses the amount of medicine, if the actual amount of expenditure is lower than the budget, then the additional part as a balanceAs an incentive, the medical institutions that have completed the assessment may retain the funds for medical insurance for collected medicines in accordance with the proportion not higher than the balance of the fund, and the specific retention ratio shall be determined by the co-ordination area according to the results of the assessment of the designated medical institutionsthe specific assessment content and the national belt purchase agreement procurement volume, priority procurement, timely settlement, as well as the control of fees, truthfully reported procurement volume and other circumstancesThe fixed-point medical institutions that fail the examination shall not pay the collected balance to retain fundssimply, the amount of medical institutionprocurement exceeds the individual budget part, does not "incentive", exceeds the purchase amount of the selected drug agreement, may not be included in the expenditure amount, the use of the same generic name and non-winning products are all included in the expenditure amount, the amount of the purchase can not be agreed, can not obtain the incentive fundsamong them, it is worth noting that the entire document did not allow the use of non-selected productsHowever, in the health insurance balance retention will be the use of non-winning products to add up, reducing the "incentive", for the price reduction of excessive products are very disadvantageousTherefore, expert analysis, the policy is also aimed at encouraging the precise reporting of each place, as well as encouraging hospitals to purchase as many winning products as possiblecan be expected from above, in the future in the volume of procurement of dry drug price moisture, health insurance balance incentives under the dual role of medical institutions will be the main procurement, the use of large price reduction of the chinese medicine, which is not selected drugs or will be a fatal blowin fact, in recent years, the market knockout of non-selected drugs is becoming increasingly serious, there are already a number of provinces and cities have issued relevant documents, regulationsFor example, as early as Last May, Fujian Health and Health Commission issued a notice to follow up the implementation of the state-organized drug centralized procurement of selected drugs clinical equipment use work, it was mentioned that the health care sector will suspend the use of the same generic name non-winning products costs, and reduce the corresponding medical insurance settlement quotaOn April 20 this year, the Nanjing Municipal Medical Security Bureau issued a "notice on promoting medical institutions, pharmaceutical enterprises to carry out centralized procurement of medical supplies (drugs) and centralized settlement work", while emphasizing that fixed-point medical institutions do not implement in accordance with the provisions, self-procurement of drugs and medical supplies, medical insurance funds will not be paidon June 15, Ningbo City, Zhejiang Province, the Health Insurance Bureau issued a notice to the whole society to solicit public medical institutions drugs, medical supplies centralized procurement of the work plan, but also made it clear that public medical institutions if the procurement of similar products other than the selected product catalog, the medical insurance fund will not payin general, in recent years, the consistency evaluation process has been promoted, more and more provinces have been in the dynamic clearance of the unselected drugs in the three unrated consistent evaluation productsIn this context, with the continuous promotion of national mining, local version of centralized band procurement and related supporting policies, more than 4000 pharmaceutical enterprises and hundreds of thousands of generic drug approvals in the country will further accelerate the processFor pharmaceutical manufacturers and distributors, it is urgent to accelerate the transformation.